Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The CONFIDENCE trial investigated the dual treatment of the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone with the SGLT2 inhibitor empagliflozin on albuminuria reduction. This biomarker analysis aims to elucidate the effect of finerenone treatment on circulating biomarkers in patients from CONFIDENCE when given in combination with empagliflozin.
Biosamples from all 798 trial participants within the safety analysis set of CONFIDENCE were included in this biomarker study. Subjects were allocated to finerenone, empagliflozin or to double treatment with finerenone and empagliflozin (1:1:1). Pre- and up to two post-randomization plasma samples, collected on study day 30 and at the end of the treatment period on day 180 (Month 6) or upon early discontinuation from the main trial, were analyzed on Olink’s ExploreHT platform. More than 5,000 biomarkers were measured. Biomarkers with a significant difference between treatment arms (based on a mixed model for repeated measurements adjusted for age and sex, were compared.
The mean age of the participants in this study was 66.5 years, 24.7% were female, all had chronic kidney disease and type 2 diabetes. At baseline, the mean estimated glomerular filtration rate (eGFR) was 54.2 mL/min/1.73 m2 (standard deviation, SD, 17.1), the mean urinary albumin-to-creatinine ratio (UACR) was 574 mg/g (SD, 2.7) and mean hemoglobin A1c was 7.3% (SD, 1.2). Renin was consistently upregulated across time by finerenone+empagliflozin. In addition, other markers relating to …… were modulated by the combination treatment of finerenone+empagliflozin vs to empagliflozin alone. The overall number of biomarkers upregulated by dual treatment with finerenone+empagliflozin (vs empagliflozin monotherapy) was higher at day 30 compared to day 180. At day 30 (but not day 180) more biomarkers were upregulated than downregulated.
This study offers insights into the dynamics of biomarker responses upon treatment of CKD patients with finerenone when given on top of SGLT2 inhibitors. Early biomarker rises may be related to temporary dips in eGFR and subsequent accumulation of proteins in plasma. For the mechanistic understanding of the mode-of-action of finerenone and SGLT2 inhibitors, later timepoints may be more informative. Renin elevation in finerenone+empagliflozin-randomized subjects (vs empagliflozin-only subjects) reflects upstream feedback regulation upon mineralocorticoid receptor blockade indicating that finerenone engages its target.
